Michael Ehlers
Neuroscience Chief Scientific Officer
Pfizer
From this contributor
A cautionary tale for autism drug development
Poorly designed animal drug studies for motor disorders have led to spurious conclusions for the clinical trials that follow. This may be even more true for autism research, says Michael Ehlers.
SHANK mutations converge at neuronal junctions in autism
SHANK3, one of the strongest candidate genes for autism, has the potential to be a molecular entry point into understanding the synaptic, developmental and circuit origins of the disorder.
SHANK mutations converge at neuronal junctions in autism
Drug zone
Rodent and stem cell models remain challenging for developing psychiatric drugs, says Michael Ehlers, chief scientific officer of neuroscience at Pfizer.
Explore more from The Transmitter
Beyond glucose: The brain may feed itself
Myelin may serve as an energy reserve for the brain, according to recent findings, prompting neuroscientists to rethink how the brain stores, shares and protects energy.
Beyond glucose: The brain may feed itself
Myelin may serve as an energy reserve for the brain, according to recent findings, prompting neuroscientists to rethink how the brain stores, shares and protects energy.
SHANK3-variant effects in primates, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 25 May.
SHANK3-variant effects in primates, and more
Here is a roundup of autism-related news and research spotted around the web for the week of 25 May.
Brain’s blue spot possesses unexpected structure-function ties
The spatial arrangement of neurons in the locus coeruleus of mice corresponds with the cells’ targets across the brain, according to a new study.
Brain’s blue spot possesses unexpected structure-function ties
The spatial arrangement of neurons in the locus coeruleus of mice corresponds with the cells’ targets across the brain, according to a new study.